Back to Search
Start Over
Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing.
- Source :
- Clinical Pharmacology & Therapeutics; Mar2011, Vol. 89 Issue 3, p387-391, 5p
- Publication Year :
- 2011
-
Abstract
- Thiopurine methyltransferase (TPMT) activity exhibits monogenic co-dominant inheritance, with ethnic differences in the frequency of occurrence of variant alleles. With conventional thiopurine doses, homozygous TPMT-deficient patients (~1 in 178 to 1 in 3,736 individuals with two nonfunctional TPMT alleles) experience severe myelosuppression, 30-60% of individuals who are heterozygotes (~3-14% of the population) show moderate toxicity, and homozygous wild-type individuals (~86-97% of the population) show lower active thioguanine nucleolides and less myelosuppression. We provide dosing recommendations (updates at http://www.pharmgkb.org) for azathioprine, mercaptopurine (MP), and thioguanine based on TPMT genotype. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00099236
- Volume :
- 89
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- Clinical Pharmacology & Therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 58146026
- Full Text :
- https://doi.org/10.1038/clpt.2010.320